Dataset Information


Mutation and Transmission Profiles of Second-Line Drug Resistance in Clinical Isolates of Drug-Resistant Mycobacterium tuberculosis From Hebei Province, China.

ABSTRACT: The emergence of drug-resistant tuberculosis (TB) is involved in ineffective treatment of TB, especially multidrug resistant/extensively resistant TB (MDR/XDR-TB), leading to acquired resistance and transmission of drug-resistant strains. Second-line drugs (SLD), including both fluoroquinolones and injectable drugs, were commonly proved to be the effective drugs for treatment of drug-resistant TB. The purpose of this study was to investigate the prevalence of SLD-resistant strains and its specific mutations in drug-resistant Mycobacterium tuberculosis clinical isolates, and to acknowledge the transmission pattern of SLD resistance strains in Hebei. The genes gyrA, gyrB, rrs, eis promoter and tlyA of 257 drug-resistant clinical isolates were sequenced to identify mutations that could be responsible for resistance against fluoroquinolones and second-line injectable drugs. Each isolate was genotyped by Spoligotyping and 15-loci MIRU-VNTR. Our results indicated that 48.2% isolates were resistant to at least one of five SLD. Of them, 37.7% isolates were resistant to fluoroquinolones and 24.5% isolates were resistant to second-line injectable drugs. Mutations in genes gyrA, gyrB, rrs, eis promoter and tlyA were detected in 73 (75.3%), 7 (7.2%), 24 (38.1%), 5 (7.9%), and 3 (4.8%) isolates, respectively. The most prevalent mutations were the D94G (23.7%) in gyrA gene and the A1401G (33.3%) in rrs gene. A combination of gyrA, rrs and eis promoter can act as a valuable predicator for predicting XDR phenotype. These results highlight the development of rapid diagnosis are the effective manners for the control of SLD-TB or XDR-TB.


PROVIDER: S-EPMC6692474 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2011-01-01 | S-EPMC3095995 | BioStudies
1000-01-01 | S-EPMC3625432 | BioStudies
1000-01-01 | S-EPMC6006251 | BioStudies
2019-01-01 | S-EPMC6617586 | BioStudies
2014-01-01 | S-EPMC3957771 | BioStudies
2013-01-01 | S-EPMC3671172 | BioStudies
2017-01-01 | S-EPMC5571295 | BioStudies
2016-01-01 | S-EPMC4879296 | BioStudies
2018-01-01 | S-EPMC6169422 | BioStudies
2019-01-01 | S-EPMC6963291 | BioStudies